Trump and Xi meet this week. The November deadline matters more.

What happened

Xi pays a state visit to the US from September 23 to 25, his first White House visit since 2015, with the summit meeting on September 24 and a state dinner attended by the heads of several American technology companies. Preparatory talks between Treasury Secretary Bessent, Trade Representative Greer and Vice Premier He Lifeng on September 20 produced no agreement on Washington's proposed three-to-six-month truce extension, with divisions persisting over rare earths, technology restrictions and tariffs.

The agenda repeats the May meeting's three Ts (trade, technology and Taiwan), with artificial intelligence now at the top for the first time at leader level. Both sides also want to lock in the calendar: Trump at APEC in November, Xi at the G20 in Miami in December, keeping leader-level summitry alive through the November 10 deadline.

Impact on our Investment Case

AI and robotics: the discount, not the technology, is the variable

Chinese AI enters this negotiation from strength. Open-weight models (Alibaba's Qwen among them) keep gaining global adoption on cost and performance, and every restriction on closed US models widens their reach. For US chipmakers with meaningful China revenue (Nvidia, AMD), that market now depends on both capitals: Washington sets what may be sold, while Beijing discourages domestic buyers from taking it. An extension of the US pause alone reopens little; movement on both sides would. Markets nonetheless lean constructive: US semiconductor and Hong Kong technology names have firmed into the summit as investors price rising odds of a truce extension.

On robotics, Xpeng commissioned on September 8 what it describes as the first automated production line for advanced humanoid robots, with its IRON robot walking off the line autonomously and mass production slated for year-end. The automotive-grade manufacturing logic behind it is the playbook that took Chinese EVs from policy project to global dominance in a decade; we expect the same cost-curve dynamics in humanoids.

China Technology: restrictions as catalyst

Export controls have become one of the strongest theses inside our China Technology strategy, not despite restrictions but because of them: when Western supply chains close, Chinese firms build domestic alternatives faster than policymakers expect, from AI chips (Cambricon) to semiconductor equipment (Naura). The new intelligent connected NEV Five-Year Plan, issued September 11, adds large-scale autonomous driving deployment and an AI-plus-automotive initiative to that substitution logic. Any relaxation of chip controls would reduce the platform-ecosystem overhang without altering the self-reliance trajectory: Beijing spent the truce building enforcement and traceability machinery, not dismantling it.

Power Revolution: clean tech in the crossfire

China's exports of the "new three" (EVs, lithium batteries, solar) rose 51% year on year in July to $23.25bn, led by a near-doubling of EV shipments, while European anti-dumping and anti-subsidy probes multiply. The rare earth angle cuts across every strategy: China holds around 60% of mined supply of magnet rare earths, over 90% of refining and nearly 95% of magnet production. Whether the October 2025 control suspension lapses, is extended or returns selectively is the most consequential open question for the energy transition supply chain, with the exposure running through magnet-dependent segments (EV drivetrains, wind turbines, robotics actuators) rather than batteries or solar, where rare earth content is negligible. For CATL, the live question is tariff escalation in its export markets, not rare earths.

Biotech 360: the Five-Year Plan nobody is talking about

On September 18, ten ministries jointly issued the pharmaceutical industry's Five-Year Plan, targeting at least 25% of global first-in-class drugs from China by 2030, sector revenue above 3.5tn yuan, and innovative drug growth above 20% annually, with AI embedded across the value chain. Our holdings sit in the priority areas the plan identifies: oncology, ADC formats and cell therapy (Remegen , CStone Pharmaceuticals). On the US side, the BIOSECURE Act became law in December and the first list of "biotechnology companies of concern" is due by December 18, 2026: the question is no longer whether a list exists but who lands on it, with equipment and service providers, not drug innovators, in the primary line of fire. Out-licensing meanwhile shows Western pharma voting with its balance sheet: a record $135.7bn of cross-border deals in 2025 and more than $100bn already by mid-2026, including AbbVie Inc's agreement with Remegen worth up to $5.6bn.

Escalation and de-escalation are both investable outcomes, but not for the same companies: tighter controls accelerate the domestic substitution names, while relaxation mostly compresses the discount on platforms and US chipmakers. Across the four strategies, our exposure deliberately spans both legs, concentrated where these plans direct capital: our AI & Robotics portfolio carries over 20% China exposure, and our China Technology strategy is by construction fully invested in the domestic ecosystem, with pure A/H-share exposure and no ADRs.

Our Takeaway

The summit is a risk management event, not a return generation event. Nothing on Thursday's agenda creates the environment our holdings need; at best it confirms that environment remains the operating assumption on both sides. The structural facts are unchanged by any handshake: the truce architecture suspends rather than removes a single control (what Washington paused is the extension of chip restrictions to majority-owned subsidiaries of listed entities, the 50% affiliates rule, not new restrictions altogether), the heavy rare earth restrictions never lapsed, and both governments spent the pause building enforcement capacity rather than winding it down. Meanwhile Beijing keeps publishing procurement schedules dressed as plans, two of them this month alone.

That is why the November 10 expiries matter more than Thursday's handshake: three suspensions converge on one date, seven weeks after the summit and a week after the midterms. An extension can be announced at any point before then; what matters is whether each suspension rolls, lapses or returns selectively. We expect extension, and foreign capital is not waiting for it: overseas holdings of A-shares reached a record 4tn yuan in the first half, increasingly allocated to technology. This is the normalization we flagged in our December note as the upside. What the coming weeks decide is whether it continues undisturbed.